RxDoctor Payments Data

Maria Delie Jumagdao Sakai, MD

Geriatric Medicine · Gilroy, CANPI 1205025996

Payments from drug & device makers

$1,650in general payments, 2019–2025

Across 108 payments — averaging $15.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$263
  • Boehringer Ingelheim$173
  • Novo Nordisk$152
  • Johnson & Johnson$149
  • Amgen$146
  • Merck$141
  • plus $627 from 13 others

What the payments were for

  • Food & beverage$1,63899%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,650 in reported general payments places this provider in the 80th percentile of 494 geriatric medicine providers in California.

See all geriatric medicine providers in California

Medicare billing

Part B allowed, 2024
$234,678
Medicare patients
291
Services billed
1,897

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin111$100,364
TrulicityDulaglutide53$57,192
OzempicSemaglutide38$35,245
EliquisApixaban52$32,847
FarxigaDapagliflozin Propanediol25$28,831
JanuviaSitagliptin Phosphate30$23,365
TradjentaLinagliptin34$18,911
EntrestoSacubitril/Valsartan32$13,720
MounjaroTirzepatide13$10,892
Breo ElliptaFluticasone/Vilanterol15$6,873
Atorvastatin Calcium381$4,319
Levothyroxine Sodium264$3,181
Gabapentin136$2,664
Ezetimibe45$2,645
Rosuvastatin Calcium157$2,298

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$173$119,274145 claims
Lilly USA, LLCTrulicity, Mounjaro$73$68,08466 claims
Novo NordiskOzempic$152$35,24538 claims
PfizerEliquis, Paxlovid$54$34,25173 claims
AstraZenecaFarxiga$128$28,83125 claims
MerckJanuvia$141$23,36530 claims
GSKBreo Ellipta$263$6,87315 claims
AbbVieSynthroid$29$1,24622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 494 geriatric medicine providers in California.

Other geriatric medicine in Gilroy

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →